Evidence map›Paper›PMID 35900966›Full record

ArticlePloS one2022

Does a rare mutation in PTPRA contribute to the development of Parkinson's disease in an Australian multi-incident family?

Melissa A Hill, Steven R Bentley, Tara L Walker, George D Mellick, Stephen A Wood, Alex M Sykes

Open access · goldAbstract readCase Reports
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Melissa A HillGriffith Institute for Drug Discovery, Griffith University, Nathan, Australia.
Steven R BentleyGriffith Institute for Drug Discovery, Griffith University, Nathan, Australia.
Tara L WalkerQueensland Brain Institute, University of Queensland, St Lucia, Australia.
George D MellickGriffith Institute for Drug Discovery, Griffith University, Nathan, Australia.
Stephen A WoodGriffith Institute for Drug Discovery, Griffith University, Nathan, Australia.
Alex M SykesGriffith Institute for Drug Discovery, Griffith University, Nathan, Australia.ORCID 0000-0001-8981-6652
Griffith University · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The genetic study of multi-incident families is a powerful tool to investigate genetic contributions to the development of Parkinson's disease. In this study, we identified the rare PTPRA p.R223W variant as one of three putative genetic factors potentially contributing to disease in an Australian family with incomplete penetrance. Whole exome sequencing identified these mutations in three affected cousins. The rare PTPRA missense variant was predicted to be damaging and was absent from 3,842 alleles from PD cases. Overexpression of the wild-type RPTPα and R223W mutant in HEK293T cells identified that the R223W mutation did not impair RPTPα expression levels or alter its trafficking to the plasma membrane. The R223W mutation did alter proteolytic processing of RPTPα, resulting in the accumulation of a cleavage product. The mutation also resulted in decreased activation of Src family kinases. The functional consequences of this variant, either alone or in concert with the other identified genetic variants, highlights that even minor changes in normal cellular function may increase the risk of developing PD.

Indexed as

Parkinson DiseaseAustraliaExome SequencingGenetic Predisposition to DiseaseHEK293 CellsHumansMutationReceptor-Like Protein Tyrosine Phosphatases, Class 4PTPRA protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 4

Identifiers

PMID35900966
PMCPMC9333306
OpenAlexW4288436408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.